Loss of NLRP3 reduces oxidative stress and polarizes intratumor macrophages to attenuate immune attack on endometrial cancer

Abstract

IntroductionThe interaction between endometrial cancer (EMC) cells and intratumoral macrophages plays a significant role in the development of the disease. PYD domains-containing protein 3 (NLRP3) inflammasome formation triggers caspase-1/IL-1β signaling pathways and produces reactive oxygen species (ROS) in macrophages. However, the role of NLRP3-regulated ROS production in macrophage polarization and the subsequent growth and metastasis of EMC remains unknown.MethodsWe conducted bioinformatic analysis to compare NLRP3 levels in intratumoral macrophages from EMC and normal endometrium. In vitro experiments involved knocking out NLRP3 in macrophages to shift the polarization from an anti-inflammatory M1-like phenotype to a proinflammatory M2-like phenotype and reduce ROS production. The impact of NLRP3 depletion on the growth, invasion, and metastasis of co-cultured EMC cells was assessed. We also evaluated the effect of NLRP3 depletion in macrophages on the growth and metastasis of implanted EMC cells in mice.ResultsOur bioinformatic analysis showed significantly lower NLRP3 levels in intratumoral macrophages from EMC than those from normal endometrium. Knocking out NLRP3 in macrophages shifted their polarization to a proinflammatory M2-like phenotype and significantly reduced ROS production. NLRP3 depletion in M2-polarized macrophages increased the growth, invasion, and metastasis of co-cultured EMC cells. NLRP3 depletion in M1-polarized macrophages reduced phagocytic potential, which resulted in weakened immune defense against EMC. Additionally, NLRP3 depletion in macrophages significantly increased the growth and metastasis of implanted EMC cells in mice, likely due to compromised phagocytosis by macrophages and a reduction in cytotoxic CD8+ T cells.DiscussionOur results suggest that NLRP3 plays a significant role in regulating macrophage polarization, oxidative stress, and immune response against EMC. NLRP3 depletion alters the polarization of intratumoral macrophages, leading to weakened immune defense against EMC cells. The reduction in ROS production by the loss of NLRP3 may have implications for the development of novel treatment strategies for EMC.

KIF23 promotes cervical cancer progression via inhibiting NLRP3‐mediated pyroptosis

“…32 The reduction of oxidative stress and polarization of intratumor macrophages is linked to NLRP3 loss in alleviating endometrial cancer. 33 MiR-22 is able to restrain cell viability of ovarian cancer cells, which is mediated by NLRP3 and PI3K/AKT signaling pathway. 34 Nigericin or in combination with LPS exert a suppressive role in the cell viability and proliferation of breast cancer cells.…”

Establishment of an immunogenic cell death-related model for prognostic prediction and identification of therapeutic targets in endometrial carcinoma

“…Conversely, polarization of TAMs to the M1 phenotype can inhibit tumor growth [ 37 ]. Previous studies have demonstrated a negative correlation between infiltration of M2-like TAMs and the prognosis of EC [ 38 – 40 ]. Our findings indicate that the ICD-high group exhibited higher infiltration of M2 macrophages compared to the ICD-low group, with a positive correlation between risk score and M2 macrophages.…”

Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma

“…Notably, the NOD-like receptors have been identified as crucial factors in tumorigenesis, angiogenesis, cancer stemness, and chemoresistance. In endometrial cancer (EMC), dysregulation of the NOD-like receptor family protein (NLRP) has been shown to impair the phagocytic function of macrophages and reduce the CD + T cell population, thereby promoting the growth, invasion, and metastasis of EMC cells (Zhu et al, 2023). Furthermore, recent research has revealed that tumor cells can utilize lipids secreted by adipocytes to promote tumor progression and chemoresistance through metabolic reprogramming.…”